Film coating section references
1. Z. Ayenew et al., Recent Patents on Drug Deliv. & Formul.
3 (1), 26–39 (2009).
2. BASF SE, Kollicoat Smartseal Technical Information (Ludwigshafen, Germany), Jan. 2011.
3. K. Kolter, F. Guth, and M. Angel, "Physiochemical Characteristics of a New Aqueous Polymer Designed for Taste-Masking
and Moisture Protection," presented by BASF at AAPS Annual Meeting and Exposition, New Orleans, Nov, 14–18, 2010.
Formulation development and manufacturing
Despite the intensification of biologic-based drug development, solid dosage forms are the mainstay in the pharmaceutical
industry. Changing regulatory requirements, increased cost pressures, and the need to innovate for better product life-cycle
management and product differentiation, are leading pharmaceutical companies to seek ways to improve development and manufacturing.
Pharmaceutical Technology recently held an webcast to more fully examine the current and future direction in formulation development, dosage forms,
and manufacturing of solid-dosage products, including the role of continuous processing and FDA's quality by design (QbD)
initiative. Participating in the webcast, which was held Mar. 1, 2011, was Robin H. Bogner, R.Ph., Ph.D., associate professor
of pharmaceutics in the Department of Pharmaceutical Science at the University of Connecticut, to discuss technical advances
in solid-dosage formulations and dosage forms. John Groskoph, senior director of new products CMC, global chemistry manufacturing
and controls at Pfizer, discussed QbD in solid-dosage manufacturing.
External development and manufacturing also are becoming more important in a pharmaceutical company's strategy. In another
webcast, Pharmaceutical Technology examined how to optimize outsourcing CMC development and manufacturing. The webcast, which was broadcast on Mar. 8, 2011,
featured Clive V. Bennett, nonexecutive chairman of Halo Pharmaceutical, Gregg Brandyberry, CEO of Wildfire Commerce and senior
advisor of A.T. Kearney Procurement and Analytic Solutions, and former vice-president of procurement of global systems and
operations at GlaxoSmithKline, and George Bobotas, PhD, and chief scientific officer at Halo Pharmaceutical. On-demand viewing
on both webcasts are available in the multimedia section at